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Passive immunity is defined as a particular antigen re-
sistance provided by external antibodies. It can be either 
naturally or artificially acquired. Natural passive immu-
nization occurs during pregnancy and breast-feeding 
in mammals and during hatching in birds. Maternal an-
tibodies are passed through the placenta and milk in 
mammals and through the egg yolk in birds. Artificial 
passive immunity is acquired by injection of either se-
rum from immunized (or infected) individuals or anti-
body preparations. Many independent research groups 
worked on selection, verification and detailed characteri-
zation of polyclonal and monoclonal antibodies against 
the influenza virus. Numerous antibody preparations 
were tested in a variety of in vitro and in vivo experi-
ments for their efficacy to neutralize the virus. Here, we 
describe types of antibodies tested in such experiments 
and their viral targets, review approaches resulting in 
identification of broadly neutralizing antibodies and 
discuss methods used to demonstrate their protective 
effects. Finally, we shortly discuss the phenomenon of 
maternal antibody transfer as a way of effective care for 
young individuals and as an interfering factor in early 
vaccination. 
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INTRODUCTION
Antibodies (Abs) are glycoproteins produced by acti-
vated B cells. They are able to bind toxic and antigenic 
proteins of pathogens. Some Abs can directly neutralize 
pathogens and/or they can evoke a potent antibody-
dependent cell-mediated cytotoxicity (ADCC) and com-
plement dependent cytotoxicity (CDC). Neutralizing Abs 
defend organisms (or cells when tested in vitro) against 
pathogens by blocking essential functions of their target 
antigens. The term “broadly neutralizing Ab” means that 
such an Ab can recognize and neutralize multiple vari-
ants of highly variable antigens, which is particularly im-
portant in protection against fast mutating viruses, such 
as the influenza virus.
Artificial passive immunization relies on administra-
tion of pathogen-specific and neutralizing Abs present in 
the serum of an immunized individual or purified either 
from such a serum or from any protein expression sys-
tem. This process leads to curing of the existing infec-
tion (therapeutic immunization) and/or to a short-term 
protection against subsequent infections (protective im-
munization). The first successful case of artificial passive 
immunization was recorded for diphtheria therapy in the 
late 19th century (see: (Schirrmann et al., 2011; Virdi & 
Depicker, 2013) and references within). Since that time, 
passive therapy has been used under many conditions, 
including prevention of tetanus, auto inflammatory disor-
ders and neutralization of snake toxins (Keller & Stiehm, 
2000). Increasing knowledge led to huge technological 
improvement in Ab-based therapy. Direct serum trans-
fusions or Ab filtrates have been replaced by monoclo-
nal antibodies (mAbs), pre-selected in high-throughput 
screening procedures and carefully characterized by mod-
ern techniques (Brekke & Loset, 2003). Passive immuni-
zation does not cause long-term protection because of 
the relatively short Ab half-life. Yet, externally produced 
Abs can be a source of a quick, specific help to an or-
ganism in danger. Accordingly, passive immunization 
seems to be useful rather in special cases, such as pro-
tection of newborns, elderly or immune-compromised 
patients, than in preventive and broadly conducted treat-
ments. 
Reports on successful application of passive immuni-
zation include anti-fungal therapy (Bugli et al., 2013) and 
treatment of neurodegenerative syndromes such as Alz-
heimer’s disease, Parkinson’s disease, Huntington’s dis-
ease or amyotrophic lateral sclerosis (Huang et al., 2013). 
Furthermore, drugs based on mAbs, such as Infliximab 
for rheumatoid arthritis and Crohn’s disease, Palivizum-
ab for respiratory syncytial virus, Gemtuzumab for re-
lapsed acute myeloid leukemia, have been approved for 
clinical application and additional ones are being evalu-
ated in clinical trials (Brekke & Loset, 2003). Recently, 
the concept of application of Abs as therapeutic or pro-
phylactic agents in infectious diseases caused by patho-
gens such as human immunodeficiency virus or herpes 
simplex virus was reviewed and the efficacy of topical or 
systemic delivery of such antibodies discussed (Whaley & 
Zeitlin, 2013).
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Influenza viruses are constantly evolving in order to 
escape neutralizing Abs raised by previous infections 
or vaccinations. Accumulation of amino acid muta-
tions in major surface glycoproteins of the influenza 
virus (antigenic drift) results in a failure of pre-exist-
ing Abs to efficiently recognize those newer, drifted 
variants. Therefore, identification of Abs able to tar-
get the conserved neutralizing epitopes broadly shared 
among different influenza variants is important if we 
want to overcome the necessity of regular (seasonal) 
updates of anti-influenza vaccine composition and the 
ensuing problems. Studies on passive immunization 
against influenza viruses gave hope for creation of the 
pools of properly described broadly neutralizing Abs, 
ready for every possible change of the antigenic prop-
erties of the major influenza antigens. Multiple exam-
ples of such Abs and their experimental application 
in prophylactic and therapeutic treatment of influenza 
can be found in recent reviews (Clementi et al., 2012; 
Laursen & Wilson, 2013). In this review we focus 
on interesting approaches used for identification of 
neutralizing Abs and on major techniques applied to 
demonstrate their effectiveness in the virus neutraliza-
tion. We also discuss the role of natural maternal im-
munity in passive immunization against influenza.
TYPES OF ANTIBODIES AND RECOMBINANT ANTIBODY 
FRAGMENTS USED FOR EXPERIMENTAL TREATMENT 
OF INFLUENZA VIRUS 
For many years passive immunization relied on 
sera containing Ab mixtures, however development of 
molecular techniques allowed for creation of mAbs, 
which can be precisely characterized and produced 
under sterile conditions. Different variants of mAbs 
used in influenza virus challenge experiments demon-
strated protective and therapeutic effects. They include 
full-length and fragments of conventional mammalian 
immunoglobulins consisting of heavy and light chains 
(IgG), chicken yolk immunoglobulins (IgY) and heavy 
chain-only antibodies from camelides (hcIgG). Sche-
matic structures of these variants are shown in Fig. 
1. The full-length Ab consists of constant and vari-
able domains. Each variable fragment (Fv) contains 
an antigen-interaction site, the only part of the Ab 
determining its antigenic specificity. It is formed by 
variable fragments of the heavy and light chain (VH 
and VL, respectively), each built from four framework 
regions (FR) and three complementarity determining 
regions (CDR). The Fv fragment of conventional IgG 
or IgY functions only when the variable domains are 
connected by a disulfide bond (which occurs when at 
least one pair of the constant region such CH1 and 
CL1 is connected to Fv) or connected via the linker 
sequence with a single-chain variable fragment (scFv). 
Although scFv can be useful for research purposes, 
clinical application of such polypeptides is limited be-
cause of their reduced stability and shorter half-life in 
comparison to the full-length Abs. Moreover, soluble 
scFv might have its specificity altered in comparison 
to a phage-bound scFv or a scFv converted to mAb 
(Kaku et al., 2012). The scFv fused to a protein trans-
duction domain (or a cell-penetrating peptide) is called 
transbody. It can translocate across the cell membrane 
and can be easily internalized (Heng & Cao, 2005) ac-
cessing virus proteins inside the infected cells and tar-
geting internal viral proteins (Poungpair et al., 2010; 
Mukhtar et al., 2009). An Ab fragment where the VH 
and VL are connected with parts of constant frag-
ments (CH1 and CL1, respectively) is named Fab, while 
an Ab fragment obtained by cleavage of full-length 
Ab and containing two Fab fragments connected by a 
hinge forms an F(ab’)2. Obtained from hcIgG single-
Figure 1. Schematic structure of full-length conventional IgG, chicken IgY, heavy chain-only camelide IgG (hcIgG) and their various 
recombinant fragments used in passive immunization experiments against influenza virus. 
Antibody fragments and domains were labeled only for IgG (see the text for explanation).
Vol. 61       575Passive immunization against influenza
domain variable fragments (VHH, also called nano-
antibody) are smaller and can penetrate tissues better 
than conventional Abs (Tillib et al., 2013). Moreover, 
they can recognize some hidden epitopes that are in-
accessible to conventional antibodies. For some ap-
plications, especially in treatment of acute infections 
caused by variable pathogens such as highly patho-
genic influenza viruses, polyclonal antibodies (pAbs) 
might give better results than mAbs. They can be ei-
ther obtained from immunized subjects or formulated 
as a mixture of a few known mAbs (Prabakaran et al., 
2009; Rinaldi et al., 2014; Simmons et al., 2007; Wal-
lach et al., 2011).
Besides the strategy of passive immunization based on 
direct delivery of Ab variants, it is worth to mention sev-
eral approaches based on delivery of the genetic material 
encoding Ab fragments to the recipient organism. Both, 
recombinant adenoviral vectors and appropriate plasmids 
were used as tools for such DNA-based passive immu-
nization. Administration of such vaccines resulted in a 
production of expected antibodies in the recipient cells 
and in protection against a challenge with influenza virus 
(Balazs et al., 2013; Tutykhina et al., 2013; Yamazaki et 
al., 2011).
ANTIBODIES SUITABLE FOR ANTI-INFLUENZA 
TREATMENT AND THEIR VIRAL TARGETS
Viral neutralization is interpreted as the elimination 
of viral infectivity. The mechanism of action of neu-
tralizing antibodies depends on their target site (RBS 
of HA1, fusion peptide etc.) and can rely on disturb-
ing the virion binding to receptors, blocking virion 
uptake into the cells or precluding fusion of the viral 
envelope with the host endosome membrane. Neutral-
izing antibodies targeting various antigens of influenza 
virus have been described in earlier reviews, such as a 
review on monoclonal antibodies directed against vari-
Table 1. Examples of broadly neutralizing antibodies with anti-influenza virus activity confirmed in vivo.
Neutralized 
group of 
influenza 
viruses
Name Target of Ab Form of Ab Mechanism (if known) Organism, tissue, isolation method
Organisms 
used to 
confirm 
protection
References
Influenza A 
and B CR9114 HA2 mAb
blocks the HA pH-indu-
ced conformational
changes associated 
with membrane fusion
Human, periphe-
ral B-cells, Phage 
display
mice (Dreyfus et al., 2012)
Influenza A 
group 1 and 
group 2
PN-SIA28 Stem(HA1 and HA2) Fab
Human,
peripheral B-cells, 
Human modified 
hybridoma
not done (Clementi et al., 2011)
FI6, FI6v3 fusion peptide (HA2)
inhibits membrane 
fusion and perhaps 
HA0 cleavage
Human, periphe-
ral B-cells,
ferrets, 
mice
(Corti et al., 
2011)
S139/1
non-contigu-
ous conforma-
tional epitope 
near RBS (HA1)
IgG2a inhibit binding to sia-lyl-glycan receptors
Mouse, splenocy-
tes, hybridoma mice
(Yoshida et al., 
2009); (Velkov 
et al., 2013)
C05 RBS (HA1) mAb
Human, Bone 
marrow, Phage 
display
mice (Ekiert et al., 2012)
Influenza A 
group 1
CR6261 Stem(HA1 and HA2),
scFv-
-phages, 
full length 
IgG1
stabilization of pre-fu-
sion state and inhibit 
membrane fusion
Human,
FACS sorted me-
mory B-cells,
Phage display
mice
(Throsby et al., 
2008); (Velkov 
et al., 2013)
D8, F10, 
A66 HA2
scFv-Fcs*; 
IgG1**
inhibits membrane 
fusion
“Non-immune” 
antibody human 
phage display 
library, phage 
display
mice (Sui et al., 2009)
PN-SIA49 stem (HA2) IgG
Human,
peripheral B-cells, 
Human modified 
hybridoma
mice (De Marco et al., 2012)
C179 stem (HA1) IgG2a mouse mice
(Lipatov et al., 
1997; Okuno et 
al., 1993; Oku-
no et al., 1994; 
Smirnov et al., 
2000); (Dreyfus 
et al., 2013)
Influenza A 
group 2 CR8020
fusion peptide 
(HA2) mAb
prevents virion release 
in the endosome and 
inhibits the HA pH-in-
duced conformational
changes associated 
with membrane fusion, 
prevents HA0 cleavage 
by host protease
Human, FACS 
sorted memory 
B-cells, Sorting 
of immortalized 
memory B-cells 
stained with APC-
-labeled HA
mice (Ekiert et al., 2011)
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ous proteins of influenza virus (Mancini et al., 2011), 
two papers focused on broadly neutralizing antibod-
ies (Clementi et al., 2012; Laursen & Wilson, 2013), 
and an excellent review exploring the knowledge on 
the antigenic sites of H5 HA molecule (Velkov et al., 
2013). The most interesting examples of such Abs are 
provided in Table 1 and some of them (sorted accord-
ing to the target antigen) are shortly described below. 
Anti-Hemagglutinin
Hemagglutinin (HA) is the major surface protein of 
influenza virus that forms homotrimers and plays a piv-
otal role in the virus infection cycle. As a major target 
of neutralizing Abs HA is under high evolutionary pres-
sure, therefore it is the most variable protein of influ-
enza virus. Eighteen different types of HA (H1-H18) 
are known, however H17 and H18 were found only in 
American fruit bats (Tong et al., 2013). HA subtypes 
were classified into two groups, group 1 including H1, 
H2, H5, H6, H8, H9, H11, H12, H13, H16, H17 and 
H18, and group 2 with H3, H4, H7, H10, H14 and H15. 
Abs recognizing conserved epitopes within either 
globular or stem domains of hemagglutinin (HA) might 
have a neutralizing potential. Most antibodies against the 
globular domain of HA can be used as valuable diag-
nostic tools, however their broad therapeutic and pro-
phylactic use is problematic (Mancini et al., 2011). The 
antigenic drift and the antigenic shift of the HA globu-
lar domain result in the limited specificity of antibodies 
recognizing epitopes located in this domain (Okada et 
al., 2010). In contrast, the stem domain of HA is highly 
conserved across multiple HA sub-types, thus it seems 
to be a more promising target for therapeutic antibod-
ies. On the other hand, immunoglobulins against stem 
domain of HA represent only a small fraction of Abs 
raised by natural infections with influenza virus. The rea-
son is poor immunogenicity of this domain which is less 
exposed on the virus surface than the HA head domain. 
MAbs recognizing the globular domain demonstrate 
some cross-reactivity. For example, human mAb (mAb 
5J8) isolated from a healthy person and targeting a con-
formational epitope adjacent to the shallow pocket of 
the receptor-binding site (RBS) is capable of neutralizing 
H5N1 cross-
clade
1B12, 1C9 fusion peptide (HA2)
Mouse, splenocy-
tes, hybridoma mice
(Prabhu et al., 
2009a)
HAb21 conformational epitope (HA1), IgG1
probably by interfering 
with viral binding
Mouse, Splenocy-
tes, hybridoma
positive in 
pseudovi-
rus-based 
neutraliza-
tion assay
(Wu et al., 
2014)
3B1 HA1 (2 epitops)
Mouse 
scFv: hu-
man IgG1
Mouse, splenocy-
tes, hybridoma mice
(Prabhu et al., 
2009b)
FLA21.140,
conformational  
epitope proxi-
mal to the RBS 
(HA1)
Human, phage 
display library 
(Ph.D-12)
not done
(Khurana et al., 
2009); (Velkov 
et al., 2013)
3C11, 
4C12, 
3H12, 3H4,
HA1 mouse
not done,
tested only 
for virus 
neutraliza-
tion
(Du et al., 
2009)
9F4,
linear epitope 
outside RBS 
(HA1)
IgG2b
blocks the HA pH-indu-
ced conformational
changes associated 
with membrane fusion
Mouse, splenocy-
tes, hybridoma mice 
(Oh et al., 
2010)
(Velkov et al., 
2013)
AFluIgG01
membrane-
-distal globular 
head (HA1)
Human 
FAb: Fc z 
vectora 
pAc-L-Fc
inhibits binding to 
sialyl-glycan receptors 
and  inhibits the HA 
pH-induced conforma-
tional
changes associated 
with membrane fusion
Human, lym-
phocytes, phage 
library
mice
(Cao et al., 
2012)
(Sun et al., 
2009)
(Velkov et al., 
2013)
H1 cross-
clade CH65 RBS (HA)
Vk:CL + 
VH: CH1-3 
of IgG1
reduction of the amo-
unt of viral particles 
released into the su-
pernatant, reduction of 
HA in the supernatant
Human, plasmab-
last, screening 
single sorted 
plasmablast
(Whittle et al., 
2011)
(Brandenburg 
et al., 2013)
H3 subtype
D1-8
conserved and 
conformational 
epitope of HA1
scFv
Human, antibody-
-secreting plasma 
cell (ASC)
Mice (the-
rapeutic 
3dpi)
(Benjamin et 
al., 2014)
12D1 HA2 IgG1 Mouse, splenocy-tes, hybridoma
Mice (the-
raputic 
2dpi)
(Wang et al., 
2010)
Influenza B
CR8033 human mAb preventing virus pro-
geny release
Human, periphe-
ral B-cells, Phage 
display
Mice, HA1 
top of HA (Dreyfus et al., 
2012) 
CR8071 vestigial estera-se domain
human 
mAb Mice
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a broad spectrum of H1N1 viruses (Krause et al., 2011). 
Also, human mAb D1-8 that recognizes the proximal 
epitope but not within RBS, displays a neutralizing ac-
tivity against diverse H3 viruses (Benjamin et al., 2014). 
Neutralizing Abs with much broader specificity and re-
acting with the globular domain of a variety of HA sub-
types are quite rare. Such Abs seem to recognize small 
epitopes formed by the conserved elements of the RBS 
(Ekiert et al., 2012; Yoshida et al., 2009).
Various mAbs against the stem region of HA recog-
nize distinct epitopes and display varying neutralizing 
potential and diverse mechanisms of antigen binding. 
Interestingly, it has been suggested (based on struc-
tural studies with three stem-binding mAbs: CR6261, 
F10 and FI6) that the use of CDR regions from both, 
VH and VL chains, is characteristic for naturally se-
lected Abs, while the Abs selected by phage-display 
method bind to HA using only the VH encoded 
CDR(Corti et al., 2011). The cross-reactivity of neu-
tralizing mAb CR6261 isolated from human periph-
eral blood mononuclear cells is limited to influenza A 
group 1 (Throsby et al., 2008). The potent therapeutic 
activity of CR6261 was demonstrated by 100% sur-
vival of mice that received a single mAb dose 4 days 
post infection (dpi). CR6261 binds via all three CDRs 
of heavy chain to the conformational epitope (F sub-
domain) within the stem region (Corti et al., 2011). 
The F subdomain is also targeted by mAb FI6. 
This mAb displays quite a broad spectrum of cross-
reactivity; it is able to neutralize influenza A from 
both, group 1 (H1, H2, H5, H6, H8, and H9) and 
group 2 (H3, H4, H7, and H10) (Corti et al., 2011). 
FI6 showed prophylactic efficacy when administered 
at a dose of 4 mg per kg of body weight and was par-
tially protective at a dose of 2 mg/kg. The therapeutic 
potential of FI6 was also confirmed in challenge ex-
periments. All mice survived infection with A/Puerto 
Rico/8/34 (H1N1) when mAb F16 was administrated 
at a dose of 15 mg/kg, 1 or 2 dpi. Binding to the 
F subdomain of HA increases HA stability, inhibiting 
the conformational changes necessary for membrane 
fusion. The FI6 Abs seem to have quite a high poten-
tial in medical and diagnostic applications.
Two other mAbs, CR8020 and CR9114, act through 
a similar mechanism of neutralization, namely they in-
hibit the membrane fusion by blocking pH-induced 
conformational changes of HA (Dreyfus et al., 2012; 
Ekiert et al., 2011). The CR8020 Ab potently neutral-
izes viruses from group 2 of influenza A, namely a 
wide spectrum of H3N2 and H7N7 and H10N7, 
while CR9114 has a much broader spectrum of reac-
tivity and can neutralize not only influenza A but also 
B types of viruses. Interestingly, both antibodies com-
pete with each other in HA binding which suggests 
that they recognize the same epitope (Dreyfus et al., 
2012). Moreover, CR9114 recognizes a nearly identi-
cal epitope to that of CR6261 and the mechanism of 
binding is similar (three CDRs of heavy chain). Thera-
peutic treatment with 15 mg/kg of CR8020 complete-
ly prevented mortality caused by H3N2 up to 2 dpi. 
Similar dose of CR9114 was sufficient to protect ani-
mals from influenza A and B infections. Therapeutic 
potential of CR8020 has been tested in clinical trials 
(see below).
As described by other researchers, 1C9 mAb binds to 
an antigenically conserved linear epitope GLFGAIAGF, 
situated in the HA2 fusion peptide (Prabhu et al., 2009). 
Experiments with the use of a mouse model confirmed 
100% protection against H5N1 viruses from clade 1 and 
2 when administered 1 dpi, and 50% protection when 
administered 3 dpi. These antibodies were also effective 
as a prophylactic therapy when administered 1 day be-
fore challenge.
Mechanisms of HA-targeted influenza virus neu-
tralization by several previously described neutralizing 
anti-HA antibodies binding to known epitopes, were 
recently investigated by using live cell imaging and in-
fecting viruses (Brandenburg et al., 2013). Results of 
this study allowed to distinguish four physiologically 
relevant mechanisms, by which these antibodies in-
terfere with the pivotal functions of HA, namely re-
ceptor binding, membrane fusion, HA0 cleavage and 
egress of newly synthesized viruses. The HA head do-
main-binding Abs either interfere with attachment of 
the influenza virus to its cellular receptor (e.g. mAb 
CR8033) or inhibit viral egress (e.g. mAb CR8071) re-
sulting in reduction of the amount of viral particles 
released from the infected cells. Antibodies against 
the stem (e.g. mAbs CR6261, CR8020) overlap with 
the fusion peptide and inhibit membrane fusion. Al-
ternatively, they can bind close to the cleavage site 
and prevent cleavage of HA0 into HA1 and HA2. As 
a consequence, conformational changes of HA, which 
are essential for infection, are inhibited. This mecha-
nism of virus neutralization (inhibiting the membrane 
fusion) does not decrease the amounts of viral parti-
cles released from the cell but causes the released par-
ticles to be non-infectious.
Anti-Neuraminidase
Neuraminidase (NA) is the second most abundant 
influenza glycoprotein that is localized in the external 
viral membrane, and it exists as a homotetramer. It is 
less variable than HA, but it also has a tendency to 
undergo antigenic shift and antigenic drift. Anti-NA 
Abs do not neutralize the virus infectivity but they 
limit the infection by impairing the efficient release 
of the virus from infected cells, which hampers virus 
shedding, thus reducing severity of the illness (Manci-
ni et al., 2011). Four antigenic sites were identified on 
NA. Some anti-NA Abs inhibit the sialidase activity 
of NA and, in consequence, block viral release from 
the host cell (Gamblin & Skehel, 2010). They can 
also reinforce anti-influenza virus response by evoking 
ADCC (Mozdzanowska et al., 1999). 
Two broadly cross-reactive NA-specific mAbs (1H5 
and 3H10) interacting with conserved conformational 
epitope were recently demonstrated to possess a pro-
phylactic efficacy in mice (Wan et al., 2013). Interesting 
results were also reported for mAb targeting the highly 
conserved linear epitope of NA (ILRTQESE/SC located 
between amino acids 222-230). These Abs were able to 
inhibit all nine types of NA in vitro and provided a het-
ero-subtypic protection in mice challenged with mouse-
adapted H1N1 and H3N2, representing group 1 and 
2 viruses, respectively (Doyle et al., 2013). In contrast, 
regular administration of other anti-NA mAb, 2B9, to 
mice and ferrets resulted only in 50% protection in both 
animal species against A/Vietnam/1203/04(H5N1) virus 
(Shoji et al., 2011).
Anti-M2 protein
The M2 protein is located in viral envelope and forms 
a homotetrameric proton-selective channel, active in 
acidic pH (Iwatsuki-Horimoto et al., 2006). Extracellular 
part of M2 (M2e) is strongly conserved among all influ-
enza A viruses. Therefore, despite its poor immunogenic 
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ability and absence of anti-M2e Abs during a natural in-
fection, it is a promising candidate for broadly-reactive 
Abs (Mancini et al., 2011). Anti-M2e mAbs do not have 
neutralization activities but they can reduce virus rep-
lication by ADCC and CDC (Wang et al., 2008). Hu-
man M2-specific mAb TCN-032 had therapeutic activity 
against H5N1 in vivo and significantly reduced mortality 
in case of mice challenge with H1N1 (Grandea et al., 
2010). Binding of Ab to the highly conserved N-termi-
nal part of M2e also seems to restrict the virus escape. 
Therapeutic potential of TCN-032 is being tested in clin-
ical trials (see below). 
It is worth to note that mAb D005  had prophylac-
tic and therapeutic activities in vivo in mice infected with 
mouse-adapted virus A/Puerto Rico/8/1934 (H1N1), 
when administered as either human scFv fused to the 
mouse Fc-γ2c domain or as human IgG1κ antibody 
(Beerli et al., 2009).
Anti-Internal proteins
Other proteins of influenza virus, because of their in-
ternal character, do not interact directly with Abs and do 
not induce production of virus neutralizing Abs. How-
ever, they might increase viral clearance by mechanisms 
such as those reported for anti-NP induction of CDC 
(Yewdell et al., 1981) or by increase of the T cell re-
sponse (Thomas et al., 2006). It was also demonstrated 
that MDCK cells expressing anti-PB2 mAb 143/3 be-
came resistant to H5N3 infection, probably by blocking 
viral transcription (Fujimoto et al., 2013). It is worth to 
mention that PEN-HuScFv, an anti-M1 scFv fused to a 
penetration peptide from Drosophila, was able to inhibit 
binding of M1 (a highly conserved protein, involved in 
viral replication) to RNA and reduced the amount of vi-
ral particles released from the infected cell (Poungpair et 
al., 2009).
SELECTION OF ANTIBODIES USEFUL IN  
ANTI-INFLUENZA TREATMENT
The choice of the isolation method is crucial for 
properties of the resulting Abs. Three very important 
decisions to be considered during the design stage of 
such experiments include: (i) a type of donor(s) species 
or cells, (ii) an organ used as a source of Ab or its gene 
and (iii) a selection technique (Fig. 2).
Type of donor and source of antibody and its gene 
Although genetic manipulation permits for large vari-
ations among the selected Abs, every species has some 
preferences in codon usage or type of synthesized Abs, 
thus decision concerning donor species can be crucial 
to final results. Because the mice immune system is well 
described, the first monoclonal antibodies were obtained 
in this species. Still, many of therapeutic mAbs are of 
murine origin. Unfortunately, repeated administration of 
murine antibodies can cause human anti-mouse antibody 
reaction, thus their usage in clinical applications is lim-
ited (Schirrmann et al., 2011). However, some of them 
are accepted by FDA (U.S. Food and Drug Administra-
tion) (Brekke & Loset, 2003). In order to minimize the 
side effects of murine Abs, chimeric and humanized Abs 
Figure 2. Scheme of the methods used for anti-influenza antibody isolation. PBMC, peripheral blood mononuclear cells, EBVi, Epstain 
Barr virus immortalized; HA, hemagglutinin.
Vol. 61       579Passive immunization against influenza
were created and approved. Moreover, transchromosom-
ic mice engineered to produce solely human-type Abs 
are already in use (Wang et al., 2008). If a mouse donor 
is to be used, splenocytes and hybridoma selection tech-
niques are generally applied (Wu et al., 2014; Yoshida et 
al., 2009; Zebedee & Lamb, 1988). 
Modern technologies allow researchers to isolate hu-
man mAbs from bone marrow (Ekiert et al., 2012; 
Kashyap et al., 2008) or from peripheral B-cells (Beerli 
et al., 2009; Dreyfus et al., 2012; Thathaisong et al., 2008). 
Promising results concerning influenza virus neutraliza-
tion were obtained for several other donor species, in-
cluding horse (Herbreteau et al., 2014), chicken (Pitaksaj-
jakul et al., 2010; Wallach et al., 2011), camel (Tillib et al., 
2013); sheep (Rinaldi et al., 2014; Simmons et al., 2007); 
ferret (Fang et al., 2012) and guinea pig (Howard et al., 
2011). 
The pAb preparations from human serum have a 
long history of effectiveness. There are two main meth-
ods of artificial passive immunization against influenza 
for humans, namely convalescent plasma or intravenous 
immunoglobulin preparations made from pooled hu-
man plasma (Hui et al., 2013). If suitable donors are 
available, passive immunotherapy with convalescent 
plasma or with hyperimmune globulin prepared from 
convalescent plasma is a good option to treat severe 
influenza. However, when such donors are not avail-
able, intravenous immunoglobulin preparations which 
are manufactured in consecutive series reflecting im-
mune status of a population remain an interesting al-
ternative (Kubota-Koketsu et al., 2012). Efficiency of 
convalescent plasma was described by meta-analysis 
provided by Luke and co-workers (Luke et al., 2006), 
who reported that during 1918 H1N1 pandemic there 
was an overall reduction in mortality from 37% to 16% 
after such a treatment. Case study for H5N1 influenza 
treatment with convalescent plasma was also reported 
(Zhou et al., 2007). Recently, two clinical trials with 
convalescent plasma and hyperimmune IV immuno-
globulin (H-IVIG) treatment have been described (see 
the Clinical trials chapter).
If a donor is an animal, usually some kind of im-
munization protocol is used (Wang et al., 2008; Wu et 
al., 2014; Zebedee & Lamb, 1988). In case of a human 
donor, antibodies against influenza were obtained from 
vaccinated subjects (Dreyfus et al., 2012; Ekiert et al., 
2011; Throsby et al., 2008), convalescents (Hu et al., 
2012; Kashyap et al., 2008; Sun et al., 2009) and from 
defined populations, for example people born in 1915 
or earlier (Yu et al., 2008), described also as a 1918 pan-
demic survivors (Mancini et al., 2011) or designated as 
“non-immune”, which means that no special effort has 
been done to increase or measure the influenza-specific 
Abs titer of donors (Lim et al., 2008; Thathaisong et al., 
2008). Additionally, some ready to use (usually “non-
immune”) libraries, like an Ab phage display library 
(Sui et al., 2009) or intrabodies library (Mukhtar et al., 
2009) were screened for Ab fragments neutralizing in-
fluenza viruses. Material for Ab screening can be col-
lected either from a single individual (Beerli et al., 2009; 
Krause et al., 2011; Liu et al., 2004) or it can be pooled 
from a few or even tens of donors (Herbreteau et al., 
2014; Simmons et al., 2007; Sui et al., 2004; Thathaisong 
et al., 2008; Yoshida et al., 2009).
Polyclonal antibodies
pAbs purification techniques depend mostly on the 
used source. While many mammalian Abs are bound by 
protein A, G and L, main Abs of chicken eggs, IgY, do 
not, and have to be purified in other ways.
Before the development of molecular technologies, 
serum transfusions from immunized animals or from 
convalescents were used for treatment of severe dis-
eases. However, one should remember that such se-
rum could contain potentially harmful pathogens and 
factors causing anti-serum response of the recipient 
immune system. Challenge experiments in mice con-
firmed the protective effects of hyperimmune anti-
influenza serum from ferrets (Fang et al., 2012), sheep 
(Simmons et al., 2007), chicken (Shahzad et al., 2008) 
and guinea pig (Howard et al., 2011).
Polyclonal immunoglobulins and their fragments 
from different organism have been used in passive im-
munization experiments. Two recent examples of such 
pAb-based approaches include highly purified equine 
specific F(ab’)2 against H5N1, also named Fabenflu 
(Herbreteau et al., 2014) and ovine polyclonal IgG 
purified with protein G from lactating ewes (Rinaldi 
et al., 2014), both very effective in mice protection 
against influenza virus. It is also worth to mention the 
successful examples of using influenza-specific IgY 
from chicken egg yolks in mice challenge experiments; 
this inexpensive and simple technique of pAb produc-
tion and purification has many advantages (Xu et al., 
2011). At least two independent groups were able to 
demonstrate in mice models high cross-reactive poten-
tial of anti-H5N1 and anti-H1N1 IgY extracted from 
eggs of hens immunized with the inactivated H5N1 
(Wallach et al., 2011; Yang et al., 2014).
Monoclonal antibodies
Several selection techniques resulting in successful iso-
lation of broadly neutralizing anti-influenza antibodies 
are presented below. 
Hybridoma
Hybridoma is the oldest techniques enabling to ob-
tain a relatively stable cell line producing desirable mAb. 
During the standard hybridoma procedure Ab-produc-
ing mice splenocytes are fused with immortal myeloma 
cells, then the resulting aneuploid cell line supernatant 
is screened against a given antigen, which is followed 
by hybridoma cell cloning on agar or by limiting dilu-
tions and re-screening (Lerner, 1981). This technique 
has proven to be useful for producing Abs against 
M2 (Fu et al., 2009; Liu et al., 2004; Zebedee & Lamb, 
1988), HA1 (Du et al., 2009; Oh et al., 2010) and full-
length HA of subtypes H1, H2, H3 and H13 (Yoshida 
et al., 2009). More recently, anti-HA neutralizing Abs 
were isolated with a modified hybridoma technique. 
One type of those modifications uses the Epstein-Barr 
virus immortalized (EBVi) human B cells (Clementi et 
al., 2011; De Marco et al., 2012; Krause et al., 2010); 
second EBVi PBMC and human B cells fused to my-
eloma (Krause et al., 2011). Those techniques allowed 
for selection of 2D1 and 2B12 mAbs with neutralizing 
activity against both, 1918 and 2009 pandemic strains 
(Krause et al., 2010), mAb 5J8 recognizing a conserved 
non-linear epitope (residues 133, 137 and 222) on the 
globular head of H1N1 HA (Krause et al., 2011) as well 
as a broad specificity mAb such as PN-SIA49 that rec-
ognizes conserved epitopes located on the stem region 
of HA (De Marco et al., 2012) and PN-SIA-28 (Clem-
enti et al., 2011) that is able to neutralize influenza vi-
ruses A of groups 1 and 2.
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Other methods related to supernatant screening
A technique similar to hybridoma but using non im-
mortalized B-cell lines was used to obtain broadly neu-
tralizing HA-specific Abs (Corti et al., 2011). Superna-
tants of single plasma cell cultures in a medium sup-
plemented with interleukin 6 (IL-6) were screened with 
multiple parallel binding assays and cDNA of the select-
ed Abs were rescued by single-cell reverse transcription 
polymerase chain reaction (RT-PCR). Single cell RT-PCR 
was also used by other teams to obtain cDNA sequence 
of Abs broadly neutralizing H1N1 viruses, however in 
these cases the cDNA libraries were created and screen-
ing of Abs produced by transfected 293T cells (Whittle 
et al., 2011) or 293A (Wrammert et al., 2011) was per-
formed.
Phage display
Phage display has been used for years and it remains 
the gold standard for recombinant Abs production 
(Hairul Bahara et al., 2013). This technique consists of 
construction of a library expressing peptides or proteins 
as fusions with phage capsid protein which permits to 
find phages with proteins interacting with a given DNA, 
peptides or proteins. The cDNA fragments encod-
Table 2. Monoclonal and polyclonal antibody preparations in clinical trials according to Cinicaltrials.gov database [http://clinicaltrials.
gov]).
Responsible 
party
Material te-
sted Trial ID Purpose
Phase
/Status* Results (if known)
Monoclonal antibody preparations
Crucell Hol-
land BV
CR8020 NCT01938352
To compare prophylactic efficacy aga-
inst H3N2, safety, tolerability, pharma-
cokinetics, and potential immunogeni-
city of CR8020 vs. placebo.
2/C Completed March 2014.
CR8020 NCT01756950
To compare the safety, tolerability, 
pharmacokinetics and immunogenicity 
of single escalating doses of CR8020 vs. 
placebo in healthy subjects.
1/C Antibody admitted to Phase 2.
CR6261 NCT01406418
To compare the safety, tolerability, 
pharmacokinetics and immunogenicity 
of single escalating doses of CR6261 vs. 
placebo in healthy subjects.
1/C Antibody initially admitted to Phase 2.
CR8020 and 
CR6261 NCT01992276
To evaluate the rate of decline in quan-
titative viral load measured in hospitali-
zed patients with influenza A infection.
2/W
Withdrawn prior to enrollment 
due to preliminary efficacy 
results from an influenza chal-
lenge trial.
Theraclone 
Sciences, Inc.
TCN-032 NCT01719874
To compare safety and efficacy of TCN-
032 vs. placebo given to healthy adult 
volunteers that have been inoculated 
with the influenza A virus.
2/RP
Estimated study completion 
date was March 2013, but re-
cruitment is still ongoing.
TCN-032 NCT01390025
To compare the safety profile of a sin-
gle intravenous administration of TCN-
032 vs. placebo in healthy volunteers.
1/C Antibody admitted to Phase 2.
Visterra, Inc. VIS410 NCT02045472
To assess the safety, tolerability, im-
munogenicity and pharmacokinetics 
of single escalating doses of VIS410 in 
healthy volunteers.
1/NB
Functional 
Genetics Inc. FGI-101-1A6 NCT01299142
To determine the safety and tolerability 
of the anti-TSG101 human monoclonal 
antibody (FGI-101-1A6) administered to 
healthy volunteers.
1/U
Polyclonal antibody preparations
The University 
of Hong Kong
Plasma treat-
ment NCT01306773
Patients with severe 2009 pdm H1N1 
infection treated with antivirals were 
offered treatment with plasma with a 
neutralizing antibody titer of ≥ 1:160, 
harvested from patients recovering 
from the 2009 pdm H1N1 infection. 
Clinical outcome was compared with 
that of patients who declined plasma 
treatment after matching patients by 
age, sex, and disease severity scores.
NP/C
Mortality and temporal levels 
of IL-6, IL-10, and TNF-α were 
lower in the plasma treatment 
group.
H-IVIG Treat-
ment NCT01617317
Patients with severe 2009 pdm H1N1 
infection on standard antiviral treat-
ment, requiring intensive care and 
ventilatory support were randomized 
to receive H-IVIG (hyperimmune intra-
venous immunoglobulin) fractionated 
from patients who recovered from the 
2009 pdm H1N1 or normal IV immuno-
globulin manufactured before 2009 as 
control.
NP/C
H-IVIG treatment was the only 
factor that independently re-
duced mortality. This treatment 
was associated with significan-
tly lower post-treatment viral 
load. The initial serum cytokine 
level was significantly higher 
in the H-IVIG group but fell 
to a similar level 3 days after 
treatment. 
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ing such peptides or proteins are inserted as a part of 
phage’s genetic material, and their nucleotide sequence 
can be easily determined. Usually, this procedure is used 
to clone scFv (Schirrmann et al., 2011). Phage display 
succeeded in selection of many broadly neutralizing hu-
man anti-HA mAbs (Dreyfus et al., 2012; Ekiert et al., 
2012; Kashyap et al., 2008; Sui et al., 2009; Throsby et al., 
2008). Also, influenza-neutralizing chicken Fab (Pitaksa-
jjakul et al., 2010) and camel VHH (Tillib et al., 2013) 
have been obtained by this technique. The phage display 
library can be used not only for isolation of Abs but 
also for epitope’s mapping (Khurana et al., 2009; Wu et 
al., 2014). A technique called an in vivo phage display is 
known since 1996 (Babickova et al., 2013).
Yeast two-hybrid display
Yeast Gal4 transcription activator protein is an endog-
enously expressed yeast protein consisting of the DNA 
binding domain (BD) and the activation domain (AD). 
The BD and AD domains can be physically separated 
and synthesized as chimeric proteins fused with other 
proteins (X and Y, respectively). If interaction between 
the partner proteins (X and Y) occurs, it brings the sep-
arate AD and BD domains in close proximity, thereby 
reconstituting the function of Ga14 and driving expres-
sion of a downstream reporter gene (Young, 1998). This 
system was used to obtain Abs targeting the nucleopro-
tein of influenza virus (Mukhtar et al., 2009). Nucleopro-
tein gene was inserted into pGBKT7 to create a protein 
containing the GAL4 DNA-binding domain fused to 
the NP protein, which was used as a bait. Intrabodies’ 
cDNA fragments were inserted into pSF50, and then li-
brary plasmids were transformed into yeast AH109 cells 
harboring the bait plasmid. Transformed AH109 cells 
were grown on a highly selective medium. Single colo-
nies were isolated and transferred onto the QDO medi-
um with X-α-Gal. Blue clones were identified as positive 
clones indicating interaction between antigen (NP) and 
the Ab fragments.
Mammalian cell display
Mammalian cell display based on the Sindbis virus ex-
pression system was used for selection of Abs recogniz-
ing the M2e protein (Beerli et al., 2009). Briefly, in this 
technique the scFv library from B-cells was prepared in 
a plasmid allowing for cell surface localization of the re-
combinant proteins, used for cell transfection. Infected 
cells were tested by FACS (Fluorescence Activated Cell Sort-
ing) analysis for M2-binding to identify virus clones en-
coding M2-specific scFv antibodies.
Sorting of immortalized memory B-cells stained with 
allophycocyanin (APC)-labeled HA 
Supernatant screening methods usually require test-
ing of large amount of cells; for example 104 000 plasma 
cells were tested by Corti and co-workers (Corti et al., 
2011). A very fast method of Abs screening, based on 
sorting B cells stained with labeled HA was developed 
and successfully used to identify anti-HA mAbs (Ekiert 
et al., 2011). It is worth to mention that mAb CR8020 
selected by this method were already tested in Phase 2 
clinical trials (see Table 2 and the Clinical Trials chapter).
National Insti-
tute of Allergy 
and Infectious 
Diseases (NI-
AID)
Pharmaco-
kinetics of 
H-IVIG
NCT02008578
To determine the pharmacokinetic 
profile of Flu-IVIG (a type of H-IVIG) and 
assess whether antibody levels obse-
rved following Flu-IVIG transfusion are 
similar to those predicted in individuals 
with influenza A or B.
1/O
H-IVIG prepa-
ration study NCT00383071
To determine how best to use a vacci-
ne for generating high levels of H-IVIG 
in people, which can be then collected 
and used to develop a possible treat-
ment for avian influenza.
2/O
Plasma col-
lection/ pre-
parations
NCT01136057
To collect blood samples from people 
who have been exposed to the influ-
enza virus and/or who have received a 
seasonal influenza vaccine. The blood 
plasma will be processed into fresh 
frozen plasma and used in a future 
clinical trial to treat people hospitalized 
with influenza.
NP/O
Plasma col-
lection NCT00984451
To collect plasma samples from people 
who have high levels of antibodies aga-
inst the influenza A virus because they 
either have been previously infected 
with the virus or have been vaccinated 
against the infection.
NP/O
Pharmaco-
kinetics of 
H-IVIG
NCT02037282
To evaluate safety, tolerability and the 
pharmacokinetics of an anti-influenza 
H-IVG. 
1/RP
Plasma treat-
ment NCT01052480
To compare the safety, efficacy, and 
pharmacokinetics of anti-influenza pla-
sma vs. standard care in hospitalized 
participants with H1N1 or H3N2 infec-
tion at risk of severe disease. 
2/RP
Shanghai 
Public Health 
Clinical Center
Blood fix 
treatment
NCT01055990 To treat critical H1N1 patients with blood fix and further observe the effec-
tiveness and safety.
2/U
C, completed; W, withdrawn; RP, recruiting participants; NB, not yet begun; U – status unknown; NP, without designated Phase; O, ongoing
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VERIFICATION OF THE EFFICACY OF ANTI-INFLUENZA 
ANTIBODIES
Determination of the epitope recognized by mAb 
gives an important hint for evaluation of its neutraliz-
ing activity, especially in the case of Abs against proteins 
with such well characterized antigenic properties as in-
fluenza HA. Nevertheless, even if this epitope is known, 
the mechanism of neutralization of an antigen might be 
complex and might be a combination of direct and in-
direct mechanisms. Because some of them depend on 
the presence of Fc fragments, differences in virus neu-
tralization by Ab fragments and full-length Abs can be 
expected (Edwards & Dimmock, 2000). Several in vitro 
and in vivo methods can be used for examination of the 
efficiency of Ab binding and for evaluation of Ab use-
fulness in virus neutralization. 
In vitro methods
Hemagglutination inhibition (HI)
This test depends on natural ability of some viruses 
(such as influenza virus) to agglutinate red blood cells 
upon binding to their surface. Incubation of the HA an-
tigen or the entire virus with Abs binding to the recep-
tor binding site of HA will inhibit this process (Branden-
burg et al., 2013). Despite theoretical simplicity this test 
is not fully reliable. It is strongly dependent on subjec-
tive assessments, laboratory conditions and other factors, 
which can introduce some errors (Defang et al., 2012).
Microneutralization (MN) 
The theoretical assumption of this test is very similar 
to the HI test. This highly sensitive and specific test de-
pends on the presence of virus neutralizing Abs in the 
sample added to the cell culture (e.g. MDCK). The ex-
amined Abs or sera are pre-incubated with standardized 
amounts of the respective virus before its addition to the 
cells. Subsequently, the ELISA test is used to measure 
the presence of NP in the infected cells (WHO, 2013).
In vivo methods
This group of methods reflects more accurately im-
munological reactions of an organism during a viral in-
fection. Challenge with the virus is an unambiguous and 
the most important test. Each step of such tests should 
be well justified because of the associated ethical issues 
and the significant costs. An appropriate animal model 
has to be chosen depending on the virus strain used and 
its natural host (Bouvier & Lowen, 2010). Such clinical 
signs as weight loss, histopathological changes and viral 
load in tissues (nasopharynges or lung) can be assessed, 
depending on the animal model. Passive immunization, 
namely administration of neutralizing Abs combined 
with challenge with the chosen virus proves most clearly 
the efficacy and the neutralizing possibilities of the ap-
plied Abs. Several animal models are commonly used in 
immunization study against influenza virus.
Mouse (Mus musculus) is commonly used in drug devel-
opment and challenge experiments. The main advantages 
are: relatively low cost, high availability, ability of gene 
manipulations and generally available species-specific re-
agents. The main disadvantages, from the viewpoint of 
anti-influenza vaccine efficacy confirmed by challenge, is 
the lack of typical for humans sialic acid receptors with 
an α-2,6 linkage to galactose. Without prior adaptation to 
the mice model, it causes resistance of mice to human 
influenza viruses.
Ferrets (Mustela putorius) are the most representative 
small animals for human influenza disease model. This 
influenza susceptible animal has few disadvantages, in-
cluding the relatively large size, high cost of breeding 
and husbandry requirements. Its main advantage is sim-
ilarity of influenza virus infection symptoms in ferrets 
and humans. Ferrets were used as a model for an anti-
viral drug (olsetamivir, amantadine) and in a virus trans-
mission study.
Guinea Pigs (Cavia porcellus), similarly to ferrets, are 
highly susceptible to human influenza virus. However, in 
this model a high level of viral titer does not correlate 
with disease severity (which is always weaker). Moreover, 
virus infection does not spread throughout the organism 
and is limited to the respiratory tissues.
Nonhuman Primates. Rhesus macaques (Macaca mulat-
ta) are the most genetically similar to a human animals 
but this model is usually involved only in the most com-
plicated studies, such as tests of antiviral drugs, vaccine 
efficacy and examination of gene expression during virus 
infection. More details about animal models used in re-
search related to influenza can be found elsewhere (Bou-
vier & Lowen, 2010). 
Besides conventional immunization methods based 
on administration of an antigen (active immunization) 
or a specific Abs (passive immunization) other experi-
mental methods were effective in obtaining protection 
against influenza viruses. One of these methods, called 
vectored immunoprophylaxis (VIP), is based on usage 
of adeno-associated virus (AAV) expressing Abs rec-
ognizing the epitope mapped in the HA stem region 
(Balazs et al., 2013). The authors cloned the cDNA 
fragments encoding VH and VL of previously charac-
terized neutralizing mAbs (F10 and CR6261) into the 
AAV-based expression vector containing the Fc of a 
human IgG1. Next, the efficacy of the VIP method 
was tested in a mice model. Within 1 week, a single 
dose (1x10 11 genome copies) of recombinant AAV 
resulted in generation of a detectable level of human 
IgG in the serum. Expected specificity was confirmed 
in the HI test. What is worth to note, mice that re-
ceived recombinant AAV bearing the F10 sequence 
were fully protected against the H1N1 challenge. Un-
fortunately, the test in ferrets gave much less promis-
ing results. The Abs level was 100-fold lower than in 
mice and no protection was observed in the challenge 
experiments (Balazs et al., 2013). Another example of 
a similar approach was reported for mice that were 
tested in passive immunization with a recombinant 
adenovirus expressing anti-HA H5-specific single-do-
main Ab (Tutykhina et al., 2013). Instead of the classic 
scFv, the camelid single-domain antibody (sdAb) was 
used. Intranasal administration protected mice that 
received sdAbs 14 days before the challenge, against 
challenge with H5N2 virus. Moreover, combination of 
adenovirus-expressed sdAb and the recombinant sdAb 
purified from the bacterial expression system indicated 
a protective property of this approach in both pro-
phylactic and therapeutic applications (Tutykhina et 
al., 2013). In a similar approach mice were vaccinated 
with a plasmid encoding full-length Ab isolated from 
hybridoma cells (Yamazaki et al., 2011). Experimen-
tal infection with H1N1 (A/PR/8/34 strain) that was 
performed 20 days after intramuscular plasmid admin-
istration (in 3 muscles) resulted in 100% protection 
(Yamazaki et al., 2011).
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It is worth to mention that some Abs have the virus 
neutralizing activity only in vivo. Neutralization of influ-
enza virus by such Abs requires interaction between the 
Fc fragment and Ab Fc receptor for IgG suggesting that 
the mechanism of their neutralizing activity is based on 
induction of ADCC (DiLillo et al., 2014). 
Clinical trials (http://clinicaltrials.gov/)
The ClinicalTrials.gov database [http://clinicaltrials.
gov] contains information about publicly and private-
ly supported research studies conducted in the United 
States and around the world. Search of this database 
for the study related to artificial passive immunization 
strategies against influenza returned 20 trials, 3 referring 
to maternal passive transfer immunity (described in the 
chapter Maternal antibodies against influenza and mater-
nal cellular transfer of immunity) and the remaining 17 
experiments, at various phases of clinical trials or with-
out clear indication of the clinical phase, are shown in 
Table 2.
Completed trials
The safety studies (Phase 1 of clinical trials) were com-
pleted with three mAbs (CR6261, CR8020 and TCN-
032). Later, the Phase 2 trial (effectiveness) was finished 
with CR8020, however trials including both, CR6261 and 
CR8020, were withdrawn prior to enrollment due to pre-
liminary efficacy results from an influenza challenge trial.
Two other completed clinical trials were connected 
with treatments of severe pandemic influenza A (2009 
pdm H1N1) infections with human polyclonal Ig prepa-
rations. In the first one, the outcome of 20 cured pa-
tients treated with orally administered oseltamivir (75 
mg) along with 500 mL of convalescent plasma contain-
ing neutralizing Abs to 2009 pdm H1N1 was compared 
with an appropriate group treated with oral oseltamivir 
alone. Mortality, viral load as well as the levels of IL-6, 
IL-10 and TNF-α were significantly lower in the group 
that received the double treatment (Hung et al., 2011). 
Later, the efficacy of the treatment with H-IVIG (0.4 g/
kg) has been assessed by the same group (Hung et al., 
2013). The treatment correlated with reduced mortality. 
An interesting discussion regarding further research on 
H-IVIG can be found in a recent publication (Joob & 
Wiwanitkit, 2013).
Ongoing studies
All four current studies are carried out by the U.S. 
National Institute of Allergy and Infectious Diseases 
(NIAID). One is a pilot study to determine safety of an 
anti-influenza H-IVIG. The preliminary results of Phase 
2 study on development of Ab treatment for Avian Flu 
(ID No. NCT00383071) are already submitted on-line. 
The remaining two studies deal with collection of an-
ti-influenza A immune plasma.
Studies still recruiting participants/not yet begun
Three out of four, non-yet started anti-influenza pas-
sive immunization clinical studies are currently recruit-
ing participants (ID No. NCT02037282, NCT01719874, 
NCT01052480). More subjects are envisaged to be in-
volved in the next study on anti-influenza H-IVIG by 
NIAID in order to assess the pharmacokinetics of such 
treatment during longer observation period and with 
higher doses (ID No. NCT02037282).
After successful completion of Phase 1, Theraclone 
Sciences, Inc prepares Phase 2a, a double-blinded, place-
bo-controlled study of TCN-032 with subjects challenged 
with H3N2 influenza A virus (ID No. NCT01719874). 
The aim of another Phase 2 study is to assess safe-
ty, efficacy and pharmacokinetics of an immune plas-
ma preparation for influenza A treatment (ID No. 
NCT01052480). The authors plan to enroll 150 adults, 
children and pregnant women hospitalized with influenza 
A (H1N1, H3N2) at risk of a severe disease.
The mysterious VIS410 mAb (ID No. NCT02045472) 
developed by Visterra Inc. was submitted as a candidate 
to Phase 1 clinical trial. The study does not yet recruit 
participants, however, the company claims that it will 
start in 2014. Unfortunately, information about this Ab 
is limited; according to data provided by Visterra Inc. 
(http://www.visterrainc.com/pipeline/vis410.html, ac-
cessed on July 9th, 2014), it binds a unique conforma-
tional epitope on the stem region of HA that is resis-
tant to virus mutation and conserved across all influenza 
subtypes. The VIS410 Ab prevents membrane fusion be-
tween the viral and host membranes.
Studies with unknown status
Two studies (ID No. NCT01299142 and 
NCT01055990) have unknown status that has not been 
changed for over two years.
MATERNAL ANTIBODIES AGAINST INFLUENZA AND 
MATERNAL CELLULAR TRANSFER OF IMMUNITY
Every organism which has been either infected or 
vaccinated with a sufficient dose of an antigen, reacts 
with a specific response inducing a long-lasting immune 
memory. During pregnancy and lactation in mammals 
and during hatching in birds, Abs from mother’s circula-
tory system are transferred to the progeny. In mammals, 
IgG class antibodies are transferred by placental cells to 
the fetus, while IgA class antibodies are secreted into 
milk. In birds, IgY class antibodies are transferred into 
the egg yolk.
Experiments with animals clearly indicated that mater-
nal vaccination is important for protection of the off-
spring against influenza. For example, significant mater-
nal protection of young ferrets against influenza virus 
has been observed (Hwang et al., 2010; Jakeman et al., 
1989). In young mice, suckling on vaccinated mouse was 
apparently more important than thevaccination status of 
the mother, but both approaches together gave the best 
results (Zhang et al., 2013). Such effects were observed 
with both, DNA immunization and live-attenuated vac-
cines. Another interesting observation was that the pres-
ence of maternal Abs interferes with active immuniza-
tion of mice offspring (Chen et al., 2007). Therefore, it 
has been proposed by the authors that mothers and their 
offspring should not be immunized with the same vac-
cine against influenza. Similar results were obtained in 
the case of hen immunization against avian influenza 
(Maas et al., 2011).
Several clinical experiments demonstrated that vaccina-
tion against influenza during pregnancy is safe and effec-
tive and diminishes a number of episodes of respiratory 
illness with fever in infants and their hospitalization rate 
(Benowitz et al., 2010; Brydak & Nitsch-Osuch, 2014; 
Eick et al., 2011; Zaman et al., 2008). In most completed 
human trials the detailed breast-feeding-related data were 
usually not available and therefore these data cannot 
be correlated with results on vaccine efficiency. Fortu-
nately, this situation has now changed. Recently com-
pleted Phase 2 trial was comparing the postpartum im-
munization of breast-feeding women with two classical 
584           2014B. Kalenik  and others
vaccines (ID No. NCT01181323). The first results are 
already submitted on ClinicalTrials.gov website (http://
clinicaltrials.gov) with data on breast milk ELISA IgA 
and IgG titer to be added. Clinical trials to which par-
ticipants are recruited (ID No. NCT01496079, no phase 
and NCT01034254, Phase 3) add the assessments of in-
fluenza antibody titer in maternal colostrum and breast 
milk in women immunized in early or late pregnancy.
It has been known for a long time that not only Abs 
but also immune cells can be transferred via placenta 
and milk. Maternal leukocytes were discovered for the 
first time in the cord blood over 40 years ago (Desai 
& Creger, 1963). Recent data indicating that transpla-
cental transfer of cells from mother to child (known 
as maternal microchimerism) takes place in 42% of 
normal pregnancies (Eikmans et al., 2014; Jeanty et al., 
2014), provide a new perspective concerning the signif-
icance of transfer of immune system cells via placenta. 
It can be a potentially additional source of immunity 
against influenza or other infectious diseases gained 
by unimmunized and not-yet-infected child. Also in 
milk, besides the secretory IgA antibodies and previ-
ously known factors preventing bacterial infection such 
as lysozyme or lactoferrin, presence of leukocytes and 
stem cells has been confirmed (Hassiotou et al., 2012). 
Moreover, human milk contains numerous proteins, 
many of them known to possess immune properties 
(Roncada et al., 2013). Therefore, although passive im-
munity definition excludes cell transfer, complete re-
search on immunity acquired from mothers should also 
take this phenomenon into consideration. Apparently, 
passive immunization works mainly as maternal immu-
nity transferred after vaccination or infection during or 
before pregnancy/breast feeding. Reasonable vaccine 
programs for pregnant women can benefit by lowering 
hospitalization rates and fatal cases in infants less than 
6 month old to whom vaccination against influenza is 
not recommended.
CONCLUSIONS
Not always the preventive active immunization is suf-
ficient to effectively protect against influenza virus infec-
tion. Highly immunogenic epitopes of surface-exposed 
antigens of influenza virus are under strong evolutionary 
pressure to escape Ab-mediated neutralization. There-
fore, cross-reactive broadly neutralizing Abs are relatively 
rare because they are usually directed against epitopes 
with lower immunogenic potential. This phenomenon 
increases the probability of mismatch between vaccine 
strains, which are selected six month before influenza 
season, and dominant/most dangerous infection in the 
vaccinated population. Therefore, administration of pu-
rified broadly-neutralizing antibodies is sometimes the 
only way to succeed in virus clearance, despite high cost 
and time-consuming production of such antibodies. For 
the purposes of passive immunization Abs can be ap-
plied topically, by systemic injection or as a component 
of multipurpose vaccines. A short lasting protection pro-
vided by artificial passive therapies makes their massive 
usage unreasonable in prevention of infectious diseases. 
The costs and logistics of such treatments set this tech-
nique as a second line of defense against influenza virus, 
after antiviral drugs, and limit it to the very special cases 
and groups of high risk patients. Still, antibodies with 
broad-neutralizing activity might save lives during influ-
enza pandemics. 
Most of research on passive immunization against in-
fluenza focus on monoclonal full-length antibodies. They 
have longer half-life and can induce CDC and ADCC 
response. In the authors’ opinion they are the most 
promising candidates for the artificial passive treatment. 
Nevertheless, simple and quick purification of polyclonal 
antibodies from convalescent sera remains the most 
frequent way to save lives in cases of severe infections 
with influenza virus non-responding to standard antiviral 
treatment.
Further research is needed to confirm a possibility of 
virus repression by intracellulary expressed or internal-
ized recombinant antibody fragments targeting internal 
viral proteins. The HI and MN tests are the main in vitro, 
and animal challenge is the main in vivo, way of confirm-
ing passive immunization efficacy. Unfortunately, many 
antibodies are screened only against a narrow range of 
strains and administration protocols which complicates 
(if not makes impossible) their comparison. ‘Gold stand-
ard’ techniques like hybridoma and phage display are 
the most frequently used for selection of specific mAbs, 
however new technological approaches like sorting of 
immortalized memory B-cells stained with a labeled tar-
get, have already resulted in isolation of the most prom-
ising mAbs. Multiplicity of Abs and the sources of genes 
encoding Abs as well as diversity of selection methods 
increase a chance to achieve success.
Naturally acquired passive immunity — both in a 
form of Abs transferred through the placenta or milk 
and by maternal cellular transfer, is also investigated with 
growing interests. Those mechanisms are very important 
for prevention of influenza infection in children under 6 
months old for whom vaccination is not recommended, 
as well as for vaccination programs with high failure risk 
due to covering the vaccine antigen by maternal Abs.
Both artificial (with mAbs and pAbs) and natural pas-
sive immunizations are subjects of ongoing clinical trials. 
Their results might be the milestones for passive immu-
nization approaches against influenza in the future. 
Finally, it is necessary to mention that various anti-
influenza Abs can be useful in other applications, for ex-
ample in immunodiagnostics.
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